Brought to you by 
Valeant buys Dow Pharmaceutical Sciences for $277mm in cash
19 Jun 2012
Executive Summary
Valeant Pharmaceuticals International (mostly neurology and dermatology products) has agreed to acquire privately held topical dermatology therapeutics company Dow Pharmaceutical Sciences in a deal worth $285mm plus earn-outs. Valeant will pay $250mm at closing and fund a $35mm escrow account subject to indemnification claims from Valeant for 18 months after the transaction is completed. In addition, Dow is entitled to $235mm in milestones based on approval and commercial targets for some pipeline projects.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant buys Dow Pharmaceutical Sciences for $277mm in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice